Who is sponsoring NCT00789841?

NCT00789841 is sponsored by University of Aarhus.

What condition does NCT00789841 study?

NCT00789841 studies Neuroendocrine Tumor.

What drugs are being tested in NCT00789841?

Interventions: Magnetic Tracking System (MTS) and radio-opaque markers.

What is the status of NCT00789841?

NCT00789841 is currently COMPLETED.

Last reviewed 2010-10-25 · How we verify

Gastrointestinal Motility in Patients With Neuroendocrine Tumors-Effects of Sandostatin LAR

NCT00789841 COMPLETED

We will study the total gastrointestinal transit time (GITT), gastric emptying and small intestine motility in NET patients before and after treated with somatostatin analogues and compare these to healthy subjects. For this we will use radio-opaque markers and the newly developed Motility Tracking System (MTS). Hypothesis: Patients with NET and carcinoid syndrome have decreased GITT, gastric emptying and small bowel transit time and an increase in phase III MMC activity compared to healthy subjects. Treatment with somatostatin analogues increase transit times and decrease phase III MMC activity and improves the clinical symptoms.

Details

Lead sponsor	University of Aarhus
Status	COMPLETED
Enrolment	13
Start date	2008-09
Completion	2010-05

Conditions

Neuroendocrine Tumor

Interventions

Magnetic Tracking System (MTS) and radio-opaque markers

Primary outcomes

Gastrointestinal transit time in NET patients — End of the study

Countries

Denmark